High-dose vitamin therapy to slow progression of age-related macular degeneration “doesn’t cost money, it actually saves money in the long run,” a Canadian researcher told attendees of the annual meeting of the American Academy of Ophthalmology in Orlando.
Dr. Sanjay Sharma of Queens University in Kingston, Ontario, told Reuters Health prior to his presentation that by his calculations, high-dose vitamin therapy–consisting of vitamins C, E, beta-carotene and zinc–could save the US healthcare system $1.56 billion over the next 10 years if taken by patients with moderately advanced dry age-related macular degeneration.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!